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Abstract
Ribonucleases, once dismissed as uninteresting digestive en-
zymes, have been shown to have remarkable biological activities.
Onconase0, from the Northern leopard frog, is currently in
clinical trials as a cancer chemotherapeutic. Recent research has
revealed some key factors responsible for the cytotoxicity of
ribonucleases, and may lead to a new class of drugs. ß 2001
Published by Elsevier Science Ltd.
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1. Introduction
Ribonucleases are best known for their ability to cleave
RNA. Yet, a growing number of these enzymes are being
shown to have unusual biological activities. Bovine pan-
creatic ribonuclease (or RNase A; EC 3.1.27.5) was
studied extensively during the 1960s and 1970s as a model
system, in part because of its prevalence in an accessible
source (the cow pancreas) and also because of its ease of
puri¢cation and small size (14 kDa). RNase A was the ¢rst
enzyme to have its sequence determined and the third to
have its structure revealed. RNase A was also used in
many early protein folding studies. Indeed, the 1972 Nobel
Prize for Chemistry was awarded jointly to Stanford
Moore, William Stein, and Christian An¢nsen for their
collective work on RNase A. In 1984, Bruce Merri¢eld
was awarded the Nobel Prize for developing chemical syn-
thesis on a solid matrix, and he likewise used RNase A as
a model.
RNase A is but the best known member of a superfam-
ily of secretory enzymes that operate at the crossroads of
transcription and translation by catalyzing RNA degrada-
tion (Fig. 1) [1,2]. Interest in ribonucleases was renewed
after some of these proteins were shown to be much more
than digestive enzymes [3,4]. For example, angiogenin is a
plasma enzyme that promotes the growth of new blood
vessels [5], and bovine seminal ribonuclease, a unique di-
meric homolog of RNase A, has immunosuppressive, em-
bryotoxic, aspermatogenic and antitumor activities [6].
Onconase, an amphibian protein, is toxic to tumor cells
both in vitro and in vivo [7].
The unexpected biological activities of ribonucleases
present novel opportunities for treating disease. Onconase,
for example, is in phase III human clinical trials as a
cancer chemotherapeutic, and new research is revealing
the basis of its speci¢c toxicity for cancer cells. These
revelations are inspiring means to endow mammalian ri-
bonucleases with speci¢c and useful cytotoxicity [8].
2. Pancreatic-type ribonucleases
RNase A is secreted in large quantities by the bovine
pancreas, presumably to digest the large amount of RNA
produced by microbial residents of the rumen [9]. The in
vivo function of RNase A is enhanced by two exceptional
features of the enzyme ^ high catalytic activity and high
conformational stability.
RNase A catalyzes the cleavage of the P^O5
0
bond of
RNA on the 3P side of pyrimidine nucleosides (Fig. 2) [2,8]
in one of the most e⁄cient catalytic processes identi¢ed to
date (kcat/Kms 109 M31 s31 [10]). The structure of RNase
A, which resembles a kidney, is stabilized by four disul¢de
bonds that involve all eight of its cysteine residues (Fig.
3b) [11,12]. RNase A has a Tm (which is the temperature
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at the midpoint of thermal denaturation) of 62‡C [13], and
its denaturation is fully reversible [14].
Ribonucleases can be cytotoxic because cleavage of
RNA renders indecipherable its encoded information
(Fig. 1). The cytotoxicity of pancreatic-type ribonucleases
was discovered in the 1950s. In these experiments, RNase
A was shown to be toxic to tumor cells, both in vitro [15]
and in vivo [16,17]. Although e¡ects were observed only
after milligrams of enzyme were injected into solid tumors,
these early studies were the ¢rst to demonstrate the poten-
tial of pancreatic-type ribonucleases as cancer chemother-
apeutics.
3. Ribonuclease inhibitor
Remarkably, the most potent known inhibitor of RNase
A, which is secreted from cells, is a cytosolic protein. Ri-
bonuclease inhibitor (or RI; 50 kDa) constitutes 0.01^
0.1% of the total protein in the cytosol of mammalian cells
[18,19]. Homologous RI proteins from porcine (pRI) and
human (hRI) have been described in detail. Both of these
RIs contain 15 sequential leucine-rich L-K repeats ar-
ranged in the shape of a horseshoe [20]. In addition,
pRI and hRI contain 30 and 32 reduced cysteine residues,
respectively. RI requires a reducing environment (such as
the cytosol) to maintain its activity. Oxidation of a single
cysteine residue quickly leads to the oxidation of the re-
maining cysteine residues. Once oxidized, RI loses its abil-
ity to bind to RNase A and is degraded rapidly by cellular
proteases [21].
RI forms a 1:1, noncovalent complex with RNase A
(Fig. 4). The Kd value of the pRIWRNase A complex is
6.7U10314 M [22], and that of the hRIWRNase A complex
is 4.4U10314 M [23]. (These values are likely to be even
smaller in the cytosol [24].) Seven of the 12 RNase A
residues that contribute most to substrate binding or turn-
over participate in intermolecular contacts with the inhib-
itor [25,26]. The four disul¢de bonds of RNase A and the
30 reduced cysteine residues of pRI are preserved in the
complex. pRI and hRI are potent inhibitors of other mam-
malian pancreatic-type ribonucleases, including angioge-
nin and human pancreatic ribonuclease [23,27,28]. The
action of RI is, however, class-speci¢c ^ RIs from amphib-
ia and birds are ine¡ective inhibitors of mammalian pan-
creatic-type ribonucleases [29].
The biological role of RI has yet to be de¢ned rigor-
ously [19]. Because all known RI ligands are secreted ri-
bonucleases, it seems likely that RI serves to protect cel-
lular RNA should a secretory ribonuclease inadvertently
enter the cytosol. In addition, RI may regulate other bio-
logical actions of ribonucleases. Regardless of its function,
the pronounced sensitivity of RI to oxidation implies a
possible mechanism for the regulation of its inhibitory
activity.
4. Onconase
Onconase is a homolog of RNase A present in the oo-
cytes and early embryos of Rana pipiens, the Northern
leopard frog [7,30]. Discovered on the basis of its antitu-
mor activity, onconase was immediately recognized as a
promising cancer chemotherapeutic agent [31]. That onco-
nase was a ribonuclease was only discovered after its se-
quence became known [32].
The amino acid sequence of onconase is V30% identi-
cal to that of RNase A (Fig. 3a) [32]. The tertiary struc-
ture of onconase is also similar to that of RNase A (Fig.
3b) [33]. Onconase is crosslinked by four disul¢de bonds,
three of which are conserved in RNase A (Fig. 3b). The
Tm of onconase is 90‡C, nearly 30‡C higher than that of
RNase A [34], a di¡erence that is largely due to its syna-
pomorphic carboxy-terminal disul¢de bond [35]. Remov-
ing this disul¢de bond not only reduces the thermal stabil-
ity of onconase to that of RNase A, but also compromises
its cytotoxic activity. The amino-terminus of onconase is
blocked by a pyroglutamyl residue, which is formed by the
cyclization of an amino-terminal glutamine residue.
Like RNase A, onconase catalyzes cleavage of the P^O5
0
bond of RNA on the 3P side of pyrimidine nucleosides.
The principal catalytic residues of RNase A are conserved
in onconase (Fig. 3a), implying that RNase A and onco-
nase catalyze RNA cleavage using similar mechanisms.
Despite this similarity, the catalytic e⁄cacy of onconase
is much lower than that of RNase A [27,32,34,35]. Inter-
estingly, RI is not a potent inhibitor of onconase catalysis.
The Ki value for the inhibition of onconase by RI is esti-
mated to be v 1036 M, which is more than 107-fold great-
er than the Kd value for the RIWRNase A complex [27].
Onconase is a cytostatic agent that arrests the cell cycle
in G1 phase [31,36], as well as a cytotoxin [37]. The LD50
value for onconase cytotoxicity in vitro depends on the
type of cancer cell, but is frequently near 1037 M. Prolif-
erating cells are more susceptible to onconase than are
quiescent cells [38]. Correspondingly, agents that increase
the rate of cell proliferation potentiate onconase cytotox-
icity, and agents that decrease the rate of cell proliferation
reduce onconase cytotoxicity. LD50 values are even lower
when onconase is administered in combination with small-
Fig. 1. Biochemical basis for the potential cytotoxicity of ribonucleases.
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molecule chemotherapeutic agents, including tamoxifen,
tri£uoperazine, cisplatin, lovastatin, and vincristine [39^
41]. In addition to its anti-cancer activity, onconase has
intriguing anti-viral properties. At 1038 M, onconase in-
hibits HIV-1 replication in chronically infected human
cells by degrading viral RNA [42,43]. Signi¢cantly, a
1038 M dose of onconase does not kill the infected cell.
Onconase is an e¡ective chemotherapeutic agent in ani-
mals. In one study, tumor cells were injected into the in-
traperitoneal cavity of mice, and treatment with onconase
was initiated 24 h later [44]. All treatment schedules in-
creased signi¢cantly the median time to death, compared
to that of untreated animals (18 days). Weekly injections
of 40 Wg/mouse yielded the greatest number of long-term
survivors. In this test group, six of 18 mice survived for
s 220 days with no evidence for onset of disease. The
most consistent side e¡ect of onconase was weight loss,
which increased in severity with the frequency and size
of the dose.
Onconase has been tested in phase I and phase II hu-
man clinical trials for treatment of numerous solid tumors,
including lung and pancreatic cancers [45,46]. In these
trials, onconase appeared to have a favorable impact on
the median survival time of the patients. Renal toxicity is
dose-limiting, but is reversible upon discontinuation of
treatment. More recently onconase has been tested, in
combination with tamoxifen, in a phase III trial for treat-
ment of patients with advanced pancreatic adenocarcino-
ma. This trial was discontinued in 1998 because tolerated
levels of onconase did not o¡er a signi¢cant therapeutic
advantage compared to 2P-deoxy-2P,2P-di£uorocytidine
(Gemzar0). A phase III trial for treatment of malignant
mesothelioma, an asbestos-related lung cancer, is still on-
going.
5. Rana catesbeiana and Rana japonica ribonucleases
Ribonucleases with chemical and biological properties
remarkably similar to those of onconase have also been
isolated from the oocytes of Rana catesbeiana (bullfrog)
and Rana japonica (Japanese rice paddy frog) [7,30]. The
R. catesbeiana and R. japonica ribonucleases share V50%
amino acid sequence identity with onconase (Fig. 3a)
[47^49]. The structure of the R. catesbeiana ribonuclease
in solution resembles the crystalline structure of onconase
(Fig. 3b). Each of the four disul¢de bonds in the R. cates-
beiana ribonuclease has a counterpart in onconase. Also
similar to onconase, R. catesbeiana ribonuclease has un-
usually high conformational stability ^ its Tm is s 75‡C.
The R. japonica ribonuclease, which has an unknown
structure, retains the cysteine residues and stability of on-
conase (Fig. 3b). The R. catesbeiana and R. japonica ribo-
nucleases catalyze cleavage of the P^O5
0
bond of RNA 3P
to pyrimidine nucleosides. Signi¢cantly, the ribonucleo-
lytic activity of the R. catesbeiana ribonuclease is not in-
hibited by hRI [50]. The e¡ect of hRI on the R. japonica
ribonuclease is unknown.
The R. catesbeiana and the R. japonica ribonucleases are
cytotoxic to various cancer cells in vitro with LD50 values
of 1037^1036 M [51,52], and the R. catesbeiana ribonu-
clease has been shown to be an e¡ective chemotherapeutic
agent in vivo [50]. In this study, tumor cells were injected
into the intraperitoneal cavity of mice, followed by daily
i.p. injections of the R. catesbeiana ribonuclease. The sur-
vival times of treated animals were signi¢cantly higher
than those of control animals. As with onconase, treat-
ment with the R. catesbeiana ribonuclease caused weight
loss in the test animals [50].
6. The structure^function problem
The cytotoxicity of onconase is dependent on its ribo-
nucleolytic activity [27,37,53,54], as is the cytotoxicity of
the R. catesbeiana ribonuclease [55]. Although the sub-
strate speci¢city of the ribonucleolytic activity of onconase
varies from assay to assay (rRNA is degraded in cultured
cells treated with onconase [37] and tRNA is degraded
preferentially in a reticulocyte lysate [27,56]), it is clear
that cytotoxic ribonucleases cause cell death by degrading
RNA. Even though RNase A has greater ribonucleolytic
activity than does onconase or the R. catesbeiana ribonu-
clease, RNase A is far less cytotoxic.
Does RI play an integral role in ribonuclease cytotox-
icity? If so, one would expect a variant of RNase A that is
resistant to inactivation by RI to be cytotoxic. The struc-
ture of the pRIWRNase A complex suggests which residues
Fig. 2. Putative mechanism for catalysis of RNA cleavage by RNase A. His12, Lys41 and His119 are conserved in all homologous ribonucleases (see
Fig. 3a).
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Fig. 3. (a) Amino acid sequences of RNase A and three of its cytotoxic homologs. Sequences were aligned using the PILEUP program (Genetics Com-
puter Group, Version 10; Madison, WI, USA) with a gap creation penalty of 8 and a gap extension penalty of 2. Residues are numbered according to
RNase A. RNase A residues that contact porcine ribonuclease inhibitor in the pRIWRNase A complex are white on black. Conserved residues are boxed.
The three residues most important for catalysis by RNase A (His12, Lys41 and His119), and the corresponding residues in the cytotoxic homologs, are
blue. Cysteine residues are yellow. (b) Three-dimensional structures of RNase A, onconase, and the Rana catesbeiana ribonuclease. The secondary struc-
tural context of each half-cystine is indicated by H (helix), S (sheet), or L (loop). Ribbon diagrams were created with the programs MOLSCRIPT [76]
and Raster3d [77] using coordinates derived from X-ray di¡raction [12,33] or NMR spectroscopy [78].
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are essential for the interaction of these two proteins. Re-
placing Gly88, which lies in a hydrophobic pocket de¢ned
by three tryptophan residues of pRI (Fig. 4) [25], is one
option [34]. The Gly88CArg (G88R) substitution causes
steric and electrostatic strain in the enzymeWinhibitor com-
plex, decreasing the susceptibility of RNase A to inactiva-
tion by RI. The Ki value for the G88R RNase A is 104-
fold greater than that for RNase A. Moreover, the con-
formational stability and catalytic activity of the variant
RNase A are comparable to those of the wild-type RNase
A. Most signi¢cantly, the G88R RNase A is toxic to a
human leukemia cell line (LD50 7 WM) [34]. By compar-
ison, the LD50 value for onconase is 0.5 WM, and a 50 WM
dose of wild-type RNase A has no e¡ect on tumor cell
viability. It is clear that wild-type RNase A has all of
the properties necessary to be a potent cytotoxin, except
for resistance to RI.
Because the physico-chemical properties of RNase A are
well de¢ned, the G88R RNase A provides a unique op-
portunity to dissect the contributions of catalysis and con-
formational stability to ribonuclease cytotoxicity. Several
RNase A variants that include the G88R substitution
along with a second substitution in the enzymic active
site have been generated [57,58]. The side chain of Lys41
donates a hydrogen bond to the transition state during
RNA hydrolysis, and also interacts with pRI residues
Tyr430 and Asp431 in the pRIWRNase A complex (Figs.
2 and 4). The double variant Lys41CArg (K41R)/G88R
RNase A is 20-fold less susceptible to inhibition by hRI
and is threefold more cytotoxic than G88R RNase A [57].
This result is striking because the K41R substitution de-
creases ribonucleolytic activity by 102-fold. Thus, the in-
crease in Ki seems to compensate for diminished catalytic
activity.
The four disul¢de bonds in RNase A make a substantial
contribution to the conformational stability of the enzyme
(Fig. 3b). Cytotoxins with a range of Tms can be created
by adding a ¢fth disul¢de bond to G88R RNase A, or by
removing one of the native disul¢de bonds from G88R
RNase A [58]. Interestingly, as the conformational stabil-
ity of a variant increases, so does its cytotoxicity. What is
the basis for this correlation? As the conformational
stability of an RNase A variant increases, the enzyme
becomes less susceptible to proteolytic degradation [58].
The cytotoxicity of a ribonuclease appears, therefore, to
be dependent on avoiding intracellular proteolysis.
7. Cellular routing of cytotoxic ribonucleases
As cytotoxins, ribonucleases are administered extracel-
lularly. To kill cancer cells, however, cytotoxic ribonu-
cleases hydrolyze RNA ^ a cytosolic molecule. At present,
it is unclear how this extracellular protein reaches the cy-
tosol. Limited, but intriguing preliminary data do, how-
ever, suggest a route.
The ¢rst step in ribonuclease cytotoxicity is an interac-
tion between the ribonuclease and the plasma membrane
Fig. 4. Three-dimensional structure of the complex between porcine ri-
bonuclease inhibitor (red) and RNase A (blue). Ribbon diagrams were
created with the programs MOLSCRIPT [76] and Raster3d [77] using
coordinates derived from X-ray di¡raction [25].
Fig. 5. Putative cellular routing of cytotoxic pancreatic-type ribonucleases. (I) The ribonuclease ¢rst interacts with the surface of the target cell. Onco-
nase and the R. catesbeiana and R. japonica ribonucleases appear to bind receptors on the plasma membrane. (II) The ribonuclease is internalized by
endocytosis and crosses a lipid bilayer to reach the cytosol. The mechanism of bilayer transversal is unknown. (III) In the cytosol, ribonucleases en-
counter the RI protein. Ribonucleases that evade RI catalyze cleavage of cellular RNA, which leads to cell death.
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of the target cell (Fig. 5). Onconase binds to speci¢c sites
on the plasma membrane of cultured glioma cells with Kd
values of 6.2U1038 M and 2.5U1037 M [37]. Receptors
for this interaction have not been identi¢ed. It is also un-
clear if these receptors are intrinsic to the glioma cells, or
if onconase binds to other cancer cells using the same
interactions. The cytotoxic ribonucleases from R. catesbei-
ana and R. japonica also bind speci¢cally to the plasma
membrane of cancer cells. Indeed, these enzymes were ¢rst
identi¢ed as sialic acid binding lectins that agglutinate
cancer cells speci¢cally [59^61]. This agglutination is in-
hibited by sialoglycoproteins and the ganglioside fraction
of human erythrocyte membranes, but is not blocked by
monomeric sialic acid [59,60]. Agglutination is also inhib-
ited by nucleotides, indicating that the active site residues
contribute to binding [61]. Finally, pretreatment with sia-
lidase protects tumor cells from both agglutination and
cytotoxicity by the R. catesbeiana ribonuclease [51,60]. It
is likely, therefore, that the same receptor renders cancer
cells susceptible to agglutination and cytotoxicity by the R.
catesbeiana and R. japonica ribonucleases. Surprisingly,
onconase has been reported not to cause tumor cell agglu-
tination [32].
Many research groups have created fusion proteins to
enhance the interactions between ribonucleases and the
plasma membrane [62,63]. The LD50 values for the cyto-
toxicity of such targeted ribonucleases are close to nano-
molar. These fusion proteins are markedly less toxic to
cells that do not express receptors for the targeting epi-
tope. RI susceptibility has not been quantitated for most
of these proteins. In one notable exception [64], transferrin
was coupled to residue 89 of human pancreatic ribonu-
clease. Analogous to the G88R substitution in RNase A,
transferrin sterically prevents RI from binding. In addi-
tion, transferrin targets the conjugate to the surface of
cells expressing the transferrin receptor. In the presence
of retinoic acid (a small molecule that disrupts the Golgi
apparatus), the ribonuclease^transferrin conjugate is toxic
to cancer cells with an LD50 value of 2 nM. Some ribo-
nuclease fusion proteins could be cytotoxic even if they are
inhibited by RI [65]. The targeting domain of a fusion
protein enables receptor-mediated entry into the cell,
which could lead to the accumulation of ribonucleolytic
activity in the cytosol. There, the fusion protein could
titrate RI, ultimately leaving ribonucleolytic activity un-
checked.
After binding to a plasma membrane receptor, onconase
must gain access to RNA (Fig. 5). Small molecules that
inhibit ATP synthesis also abolish onconase cytotoxicity
[37]. This result is consistent with onconase entering the
cell by endocytosis, an energy-dependent process. Like ret-
inoic acid, monensin is a small molecule that disrupts in-
tracellular tra⁄cking. Both retinoic acid and monensin
potentiate onconase cytotoxicity [53], indicating that on-
conase is able to reach the cytosol more e⁄ciently in cells
with damaged vesicles. Retinoic acid may, however, alter
the intracellular routing of onconase. Brefeldin A stops
both forward and retrograde vesicular transport between
the endoplasmic reticulum and the Golgi apparatus. Bre-
feldin A blocks onconase cytotoxicity in the presence, but
not the absence, of retinoic acid [53].
Cytotoxic ribonucleases face a topological problem ^
regardless of their path into the cell, they must cross a
lipid bilayer to reach the cytosol. The location and mech-
anism of bilayer transversal is unknown. Unlike many
bacterial toxins, which have distinct catalytic and trans-
location domains [66,67], RNase A and its homologs have
but a single domain (Fig. 3b). Moreover, ribonucleases are
highly cationic, not lipophilic. In addition, their multiple
interweaving disul¢de bonds impose girth. These disul¢de
bonds must remain intact during translocation, as the re-
ducing environment of the cytosol would not permit re-
oxidation. (The disul¢de bonds of native RNase A are
virtually inaccessible to solvent [13] and have considerable
kinetic stability in a highly reducing environment [68].) It
appears that only a few molecules of a cytotoxic ribonu-
clease are required to kill a cell [69]. Hence, delineating the
transbilayer movement of ribonucleases in molecular
terms is a formidable challenge [70].
8. Basis for therapeutic index
In cell culture systems, animal models, and human clin-
ical trials, the Rana ribonucleases are more toxic to cancer
cells than to noncancer cells. The basis for this favorable
therapeutic index is unknown. Changes to the plasma
membrane ^ perhaps upregulation of a receptor ^ may
increase the susceptibility of cancer cells to cytotoxic ribo-
nucleases. Indeed, the density of sialic acid-rich ganglio-
sides is elevated in some types of cancers [71,72]. Alterna-
tively, the cellular routing of ribonucleases or cytosolic RI
levels could di¡er between cancer cells and their normal
counterparts. Finally, the rapid proliferation of cancer
cells could make them more reliant on the integrity of
their RNA (Fig. 1).
A chemotherapeutic agent based on a human protein is
likely to be preferable to one based on an amphibian pro-
tein. The Rana ribonucleases have several undesirable side
e¡ects (vide supra). Onconase is identical to its human
homolog in only 31 of its 104 residues. When ribonu-
cleases are injected into mice 50% of onconase is found
in the kidney after 3 h, compared with only 1% of human
pancreatic ribonuclease [73,74]. Renal retention could,
therefore, limit the e⁄cacy of onconase, as it limits dosage
[45,46]. Already, a dimeric variant of human pancreatic
ribonuclease, which evades hRI, has been shown to be
toxic to cancer cells in vitro [75]. Indeed, the creation
and testing of potent cytotoxic variants of human pancre-
atic ribonuclease is a most exciting development.
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9. Prospects
Recent work on cytotoxic ribonucleases is providing a
framework for the development of a new class of cancer
chemotherapeutic agents. Moreover, e¡orts to reveal the
mechanism of ribonuclease cytotoxicity are revealing new
questions for chemical biologists. Why are cancer cells
especially vulnerable to pancreatic-type ribonucleases?
How does a highly charged protein cross a lipid bilayer?
Would a small-molecule antagonist of RI potentiate the
cytotoxicity of exogenous or endogenous ribonucleases?
The plethora of basic research carried out on RNase A
during the 20th century is paying o¡ now in a most un-
expected way.
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